De novo Inflammatory Bowel Disease following Liver and Heart Transplantation: A Case Series Exploring the Role of IL-23 Pathway-Targeted Therapy
De novo IBD emerged years after SOT, with variable phenotypes despite baseline immunosuppression. IL-23 pathway inhibitors demonstrated favorable efficacy and safety in this vulnerable population, representing a promising strategy warranting further prospective evaluation.
Authors
- Chie Bujo
- Nobuhisa Akamatsu (ORCID: https://orcid.org/0000-0003-1603-5147)
- Masaru Hatano (ORCID: https://orcid.org/0000-0003-2135-3625)
- Jun Kato (ORCID: https://orcid.org/0000-0003-4832-8024)
- Yoku Hayakawa (ORCID: https://orcid.org/0000-0002-3988-2499)
- Chihiro Shiomi
- Junichi Ishida
- Fujishiro Mitsuhiro
- Sozaburo Ihara
- Norihiko Takeda
- Minoru Ono
- Yosuke Tsuji
- Kiyoshi Hasegawa
- Yujiro Nishioka
- Ken Kurokawa
Institutions
- Chiba University (JP)
- V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs (RU)
- The University of Tokyo (JP)
Publication Details
- Journal
- Inflammatory Intestinal Diseases
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1159/000550240
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00